p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy.

Authors:
Hyeon Jeong Oh
Hyeon Jeong Oh
Seoul National University Hospital
South Korea
Jeong Mo Bae
Jeong Mo Bae
Seoul National University College of Medicine
South Korea
Xianyu Wen
Xianyu Wen
Seoul National University College of Medicine
Younghoon Kim
Younghoon Kim
Chonbuk National University
Jeonju | South Korea
Kyung Ju Kim
Kyung Ju Kim
Seoul National University College of Medicine
Seoul | South Korea
Nam-Yun Cho
Nam-Yun Cho
South Korea
Jung Ho Kim
Jung Ho Kim
Australian Institute for Innovative Materials (AIIM)
Wollongong | Australia

Br J Cancer 2019 Apr 21;120(8):797-805. Epub 2019 Mar 21.

Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.

Background: We attempted to elucidate whether p53 expression or TP53 mutation status was associated with cancer-specific survival in adjuvant FOLFOX-treated patients with stage III or high-risk stage II colorectal cancer (CRC).

Methods: We analysed CRCs (N = 621) for the presence of TP53 alterations and for p53 expression, using targeted resequencing and immunohistochemistry. CRCs were grouped into four subsets according to the p53 expression status, which included p53-no, mild, moderate and strong expression.

Results: The distributions of CRCs were 19.85, 11.05, 17.7% and 51.5% in the p53-no, mild, moderate and strong expression groups, respectively. Cases in the p53-mild to moderate expression group were associated with a more frequent proximal location, undifferentiated histology, lower N category, extraglandular mucin production, microsatellite instability, CIMP-P1, CK7 expression and decreased CDX2 expression compared with those of cases of the p53-no expression and p53-strong expression groups. According to survival analysis, the p53-mild expression group showed a poor 5-year relapse-free survival (hazard ratio (HR): 2.71, 95% confidence interval (CI) = 1.60-4.60, P < 0.001) and poor 5-year cancer-specific survival (HR: 2.90, 95% CI = 1.28-6.57, P = 0.011).

Conclusions: p53-mild expression status was found to be an independent prognostic marker in adjuvant FOLFOX-treated patients with stage III and high-risk stage II CRC.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0429-2DOI Listing
April 2019
1 Read
4.836 Impact Factor

Publication Analysis

Top Keywords

p53 expression
16
expression
10
high-risk stage
8
iii high-risk
8
p53-no mild
8
mild moderate
8
colorectal cancer
8
expression group
8
expression groups
8
stage iii
8
stage colorectal
8
moderate strong
8
associated cancer-specific
8
cancer-specific survival
8
expression status
8
status associated
8
515% p53-no
4
177% 515%
4
p53-mild expression
4
1105 177%
4

References

(Supplied by CrossRef)
Article in J. Clin. Oncol.
MJ O’Connell et al.
J. Clin. Oncol. 1997
Article in J. Clin. Oncol.
T Andre et al.
J. Clin. Oncol. 2003
Article in J. Clin. Oncol.
T Andre et al.
J. Clin. Oncol. 2009
Article in J. Clin. Oncol.
JP Kuebler et al.
J. Clin. Oncol. 2007
Article in J. Clin. Oncol.
E Mamounas et al.
J. Clin. Oncol. 1999
Article in Cancer Biol. Ther.
JM Mariadason et al.
Cancer Biol. Ther. 2011
Article in Cancer Chemother. Pharmacol.
A Farina-Sarasqueta et al.
Cancer Chemother. Pharmacol. 2010
Article in Nat. Rev. Drug Discov.
A Vazquez et al.
Nat. Rev. Drug Discov. 2008
Article in Cancer Res.
PM O’Connor et al.
Cancer Res. 1997
Article in Clin. Cancer Res.
B Yang et al.
Clin. Cancer Res. 1996
Article in J. Clin. Investig.
F Bunz et al.
J. Clin. Investig. 1999

Similar Publications